{
    "clinical_study": {
        "@rank": "154603", 
        "arm_group": [
            {
                "arm_group_label": "15g Ascorbate", 
                "arm_group_type": "Experimental", 
                "description": "During radiation therapy:\nRadiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.\nAscorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }, 
            {
                "arm_group_label": "25g Ascorbate", 
                "arm_group_type": "Experimental", 
                "description": "If the 15g arm is tolerated, the study opens the 25g arm.\nDuring radiation therapy:\nRadiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.\nAscorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }, 
            {
                "arm_group_label": "50g arm", 
                "arm_group_type": "Experimental", 
                "description": "If the 25g arm is tolerated, the study opens the 50g arm.\nDuring radiation therapy:\nRadiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.\nAscorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }, 
            {
                "arm_group_label": "62.5g", 
                "arm_group_type": "Experimental", 
                "description": "If the 50g arm is tolerated, the study opens the 62.5g arm.\nDuring radiation therapy:\nRadiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.\nAscorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }, 
            {
                "arm_group_label": "75g Ascorbate", 
                "arm_group_type": "Experimental", 
                "description": "If the 62.5g arm is tolerated, the study opens the 75g arm.\nDuring radiation therapy:\nRadiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.\nAscorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }, 
            {
                "arm_group_label": "87.5g Ascorbate", 
                "arm_group_type": "Experimental", 
                "description": "If the 75g arm is tolerated, the study opens the 87.5g arm.\nDuring radiation therapy:\nRadiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.\nAscorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }, 
            {
                "arm_group_label": "100g Ascorbate", 
                "arm_group_type": "Experimental", 
                "description": "If the 87.5g arm is tolerated, the study opens the 100g arm.\nDuring radiation therapy:\nRadiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.\nAscorbate: 100 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }, 
            {
                "arm_group_label": "125g Ascorbate", 
                "arm_group_type": "Experimental", 
                "description": "If the 100g arm is tolerated, the study opens the 125g arm.\nDuring radiation therapy:\nRadiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.\nTemozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.\nAscorbate: 125 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).\nAfter radiation therapy:\nTemozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.\nAscorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate\n      (vitamin C) to standard radiation and chemotherapy for initial treatment of glioblastoma\n      multiforme (GBM)."
        }, 
        "brief_title": "A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glioblastoma", 
            "GBM", 
            "Glioblastoma Multiforme"
        ], 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "detailed_description": {
            "textblock": "This phase 1 study will test the safety of adding high dose ascorbate (vitamin C) to\n      standard chemoradiation and, after the radiation is completed, during 6 cycles of\n      temozolomide.\n\n      Standard treatment for glioblastoma multiforme (GBM) involves surgery followed by radiation\n      combined with temozolomide (a chemotherapy). After radiation, patients receive cycles of\n      temozolomide (adjuvant chemotherapy)\n\n      Participants will:\n\n        -  receive high doses of intravenous (IV) ascorbate three times a week during\n           chemoradiation\n\n        -  receive high doses of intravenous (IV) ascorbate twice a week during adjuvant\n           chemotherapy (after radiation)\n\n      This is a phase 1 study will evaluate the side effects of adding this drug to the standard\n      therapy. The dose given to a participant will be determined by how well other participants\n      have tolerated the drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have newly diagnosed (i.e., within 5 weeks), histologically or\n             cytologically confirmed glioblastoma multiforme.\n\n          -  Diagnosis must be made by surgical biopsy or excision.\n\n          -  Therapy must begin \u2264 5 weeks after surgery.\n\n          -  Age \u2265 18 years\n\n          -  ECOG performance status 0-2 (Karnofsky > 50%).\n\n          -  A complete blood count and differential must be obtained within 21 days prior to the\n             first dose of radiation, with adequate bone marrow functions as defined below:\n\n               -  Absolute neutrophil count (ANC) \u2265 1500 cells per mm3\n\n               -  Platelets \u2265 100,000 per mm3\n\n               -  Hemoglobin \u2265 8 g/dL\n\n          -  Serum blood chemistries within 21 days before the first day of radiation, as defined\n             below:\n\n               -  Creatinine \u2264 2.0 mg\n\n               -  Total bilirubin \u2264 1.5 mg/dL\n\n               -  ALT (Alanine Aminotransferase)\u2264 3 times the institutional upper limit of normal\n\n               -  AST (Aspartate Aminotransferase) \u2264 3 times the institutional upper limit of\n                  normal\n\n          -  Tolerate one text dose (15g) of ascorbate\n\n          -  Not pregnant\n\n          -  Ability to understand and willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Recurrent high grade glioma\n\n          -  G6PD (glucose-6-phosphate dehydrogenase) deficiency\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to temozolomide.\n\n          -  Significant co-morbid central nervous system disease, including but not limited to,\n             multiple sclerosis.\n\n          -  Patients who are on the following drugs and cannot have a drug substitution:\n             flecainide, methadone, amphetamines, quinidine, and chlorpropamide. High dose\n             ascorbic acid may affect urine acidification and, as a result, may affect clearance\n             rates of these drugs.\n\n          -  Prior invasive malignancies (except non-melanomatous skin cancers and carcinoma in\n             situ of the cervix or bladder) unless disease free for \u2265 5 years.\n\n          -  Patients who have received prior chemotherapy (including Gliadel wafers) for the\n             current glioma.\n\n          -  Prior radiation therapy to the head or neck, which would result in overlap of\n             radiation therapy fields.\n\n          -  Patients may not be receiving any other investigational agents.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Pregnant women are excluded from this study because ionizing radiation is a known\n             teratogen, and temozolomide is a Class D agent with the potential for teratogenic or\n             abortifacient effects.\n\n          -  Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4 (an\n             enzyme pathway) inducer, which results in lower serum levels of antiretroviral drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752491", 
            "org_study_id": "201211713", 
            "secondary_id": [
                "P30CA086862", 
                "U01CA140206"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "15g Ascorbate", 
                    "25g Ascorbate", 
                    "50g arm", 
                    "62.5g", 
                    "75g Ascorbate", 
                    "87.5g Ascorbate", 
                    "100g Ascorbate", 
                    "125g Ascorbate"
                ], 
                "description": "Intravenous infusion of high-dose ascorbate", 
                "intervention_name": "Ascorbate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ascorbic Acid", 
                    "Vitamin C"
                ]
            }, 
            {
                "arm_group_label": [
                    "15g Ascorbate", 
                    "25g Ascorbate", 
                    "50g arm", 
                    "62.5g", 
                    "75g Ascorbate", 
                    "87.5g Ascorbate", 
                    "100g Ascorbate", 
                    "125g Ascorbate"
                ], 
                "description": "Oral chemotherapeutic", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug", 
                "other_name": "Temodar"
            }, 
            {
                "arm_group_label": [
                    "15g Ascorbate", 
                    "25g Ascorbate", 
                    "50g arm", 
                    "62.5g", 
                    "75g Ascorbate", 
                    "87.5g Ascorbate", 
                    "100g Ascorbate", 
                    "125g Ascorbate"
                ], 
                "intervention_name": "Radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": "External beam radiation therapy"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ascorbic Acid", 
                "Vitamins", 
                "Temozolomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ascorbate", 
            "Ascorbic acid", 
            "Vitamin C", 
            "Radiation", 
            "Temozolomide"
        ], 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "contact": {
                "email": "sandy-vollstedt@uiowa.edu", 
                "last_name": "Sandy Vollstedt, RN, BSN", 
                "phone": "319-353-7143"
            }, 
            "contact_backup": {
                "email": "jane-hershberger@uiowa.edu", 
                "last_name": "Jane Hershberger, RN, BSN", 
                "phone": "(319) 384-7912"
            }, 
            "facility": {
                "address": {
                    "city": "Iowa City", 
                    "country": "United States", 
                    "state": "Iowa", 
                    "zip": "52242"
                }, 
                "name": "Holden Comprehensive Cancer Center at the University of Iowa"
            }, 
            "investigator": [
                {
                    "last_name": "John M Buatti, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Bryan Allen, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Carryn Anderson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Daniel Berg, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sudershan Bhatia, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kellie Bodeker, MSHS, CCRC", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Garry Buettner, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Raymond Hohl, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Rockey, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mark C Smith, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Wenqing Sun, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Brett Wagner, MA", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme", 
        "overall_contact": {
            "email": "bryan-allen@uiowa.edu", 
            "last_name": "Bryan Allen, MD, PhD", 
            "phone": "(319) 356-8538"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Radiation Oncology, The University of Iowa", 
                "last_name": "John M. Buatti, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Professor of Surgery, The University of Iowa", 
                "last_name": "Joseph J Cullen, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assess grade 3 and higher adverse events. Evaluate the frequency and severity against the published literature to determine the likely causality between ascorbate and the adverse event(s).", 
            "measure": "Number of grade 3, 4, & 5 adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Weekly during therapy for up to 10 months"
        }, 
        "reference": [
            {
                "PMID": "22728050", 
                "citation": "Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta. 2012 Dec;1826(2):443-57. doi: 10.1016/j.bbcan.2012.06.003. Epub 2012 Jun 20. Review."
            }, 
            {
                "PMID": "20068072", 
                "citation": "Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010 Jan 15;16(2):509-20. doi: 10.1158/1078-0432.CCR-09-1713. Epub 2010 Jan 12."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752491"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Iowa", 
            "investigator_full_name": "John M. Buatti", 
            "investigator_title": "Professor and Chair, Department of Radiation Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from the start of therapy (day 1, cycle 1) to documented disease progression in MRI imaging as described by MacDonald and colleagues.", 
                "measure": "Time to progression", 
                "safety_issue": "Yes", 
                "time_frame": "monthly up to 5 years post treatment"
            }, 
            {
                "description": "From start of treatment (cycle 1, day 1) until the date of death from any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "University of Iowa", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institutes of Health (NIH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Iowa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}